Ionis Pharmaceuticals (IONS) announced that GSK (GSK) has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen, an investigational antisense medicine for the treatment of patients with chronic hepatitis B infection. Ionis earned a $15M milestone payment from GSK associated with the progression of bepirovirsen into the Phase 3 clinical studies.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis Pharmaceuticals receives FDA Fast Track designation for olezarsen
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
- Royalty, Ionis enter into royalty agreement for up to $1.1B
- Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis’ genetic medicines and commercial readiness